Renaissance Technologies LLC Trims Stock Position in Personalis, Inc. (NASDAQ:PSNL)

Renaissance Technologies LLC decreased its stake in Personalis, Inc. (NASDAQ:PSNL) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 920,868 shares of the company’s stock after selling 10,243 shares during the quarter. Renaissance Technologies LLC owned approximately 1.30% of Personalis worth $5,323,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its stake in shares of Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after purchasing an additional 5,654 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Personalis by 66.6% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,168 shares of the company’s stock valued at $145,000 after buying an additional 10,065 shares during the period. Olympiad Research LP purchased a new position in Personalis in the fourth quarter valued at $59,000. SG Americas Securities LLC acquired a new position in shares of Personalis in the fourth quarter worth about $63,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Personalis during the 4th quarter worth about $64,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PSNL. Craig Hallum started coverage on Personalis in a report on Monday, March 17th. They issued a “buy” rating and a $8.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Personalis in a research note on Thursday, April 10th. Lake Street Capital lifted their price target on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Personalis in a research report on Friday, February 28th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $7.80.

Personalis Stock Down 3.0 %

Shares of PSNL opened at $3.19 on Monday. The firm’s fifty day moving average is $3.91 and its two-hundred day moving average is $4.54. The stock has a market cap of $281.70 million, a PE ratio of -1.90 and a beta of 1.89. Personalis, Inc. has a 52-week low of $1.14 and a 52-week high of $7.20.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $16.80 million for the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. As a group, research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.